3-endo-hydroxy-N,N-dimethyl-3-(m-tolylethynyl)-8-azabicyclo[3.2.1]octane-8-carboxamide

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 3-endo-hydroxy-N,N-dimethyl-3-(m-tolylethynyl)-8-azabicyclo[3.2.1]octane-8-carboxamide
• 化学式: C₁₉H₂₄N₂O₂
• 分子量: 312.412
• InChiKey: HHURHNQYUICLFV-DZFIZOCASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.39
• 重原子数：
  23.0
• 可旋转键数：
  0.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  43.78
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  N-Boc-nortropinone 在 盐酸 、 正丁基锂 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-endo-hydroxy-N,N-dimethyl-3-(m-tolylethynyl)-8-azabicyclo[3.2.1]octane-8-carboxamide
  参考文献：
  名称：

  Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and L-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis' AFQ-056 (Mavoglurant), which served us as a template for a scaffold hopping approach, generating a structurally diverse set of potent analogs. Both the limited aqueous solubility and the relatively poor metabolic stability of AFQ-056 were improved with hexahydrocyclopenta[c]pyrrole derivative 54a, which proved to be a valuable candidate for further development. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.059

文献信息

• Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators
  作者：Holger Kubas、Udo Meyer、Mirko Hechenberger、Kai-Uwe Klein、Patrick Plitt、Ronalds Zemribo、Harm W. Spexgoor、Sander G.A. van Assema、Ulrich Abel

  DOI：10.1016/j.bmcl.2013.09.059

  日期：2013.12

  The metabotropic glutamate receptor subtype 5 has evolved into a promising target for the treatment of various diseases of the central nervous system, such as Fragile X and L-DOPA induced dyskinesia. One of the most advanced clinical compound is Novartis' AFQ-056 (Mavoglurant), which served us as a template for a scaffold hopping approach, generating a structurally diverse set of potent analogs. Both the limited aqueous solubility and the relatively poor metabolic stability of AFQ-056 were improved with hexahydrocyclopenta[c]pyrrole derivative 54a, which proved to be a valuable candidate for further development. (C) 2013 Elsevier Ltd. All rights reserved.